Bavarian Nordic A/S (CPH:BAVA)

Market Cap	15.25B +11.7%
Revenue (ttm)	6.89B +13.5%
Net Income	2.44B +118.6%
EPS	30.83 +116.3%
Shares Out	77.51M
PE Ratio	6.38
Forward PE	18.16
Dividend	n/a
Ex-Dividend Date	n/a

Volume	102,827
Average Volume	247,073
Open	196.70
Previous Close	196.75
Day's Range	195.50 - 198.05
52-Week Range	123.30 - 244.80
Beta	1.13
RSI	54.66
Earnings Date	Mar 12, 2026

About Bavarian Nordic

Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV for the treatment of encephalitis viruses. It operates in the Unite...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1992
• Employees: 1,738
• Stock Exchange: Copenhagen Stock Exchange
• Ticker Symbol: BAVA

Financial Performance

In 2024, Bavarian Nordic's revenue was 5.72 billion, a decrease of -19.06% compared to the previous year's 7.06 billion. Earnings were 987.98 million, a decrease of -33.03%.